Advicenne announces the release of results of a study showing improved quality of life in patients living with DRTa and treated by ADV7103
March 30, 2022
Paris, 30 March 2022 – 6.00 pm CEST – Advicenne (Euronext: ALDVI), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announces the publication, in the peer-reviewed journal Orphanet Journal of Rare Disease, results of a study showing improvement in the long-term quality of life in patients with distal Renal Tubular Acidosis (dRTA) and treated with ADV7103.